Zhoushi Qiling Decoction Induces Apoptosis of Human Prostate Cancer Cells Via MiR-143/Bcl-2 Axis

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Jun 25

PMID 34170852

Citations 6

Authors

Hongwen Cao

Dan Wang

Renjie Gao

Lei Chen

Yigeng Feng

Dongwen Gao

Affiliations

Soon will be listed here.

Abstract

A number of traditional Chinese medicines (TCMs) are widely used in prostate cancer treatment in China. The aim of this study was to test the efficacy of a TCM, Zhoushi Qiling Decoction (ZQD), in combination with androgen deprivation therapy (ADT) and explore its underlying mechanism. A total of 151 patients were recruited to receive ADT treatment or ADT+ZQD treatment. The survival of patients who received ADT+ZQD treatment was significantly higher than those who received ADT therapy only. DU145 prostate cancer cells were treated with ZQD (50 mg/mL) for 24 h and expression levels of an array of miRNAs were examined. Our results suggested that miR-143 demonstrated prominent upregulation in DU145 cells after treatment with ZQD. In patient serum samples, miR-143 expression was also significantly upregulated after ADT+ZQE treatment, which was however absent in patients treated with ADT only. In DU145 cells, ZQD treatment led to a dose-dependent increase in apoptosis, which could be reduced by anti-miR-143 treatment. There was a binding site between miR-143 and B cell CLL/lymphoma-2 (Bcl-2) and ZQD treatment reduced Bcl-2 expression. ZQD treatment led to increased caspase-3 and Bax expression. ZQD treatment could promote apoptosis of prostate cancer cells by promoting miR-143 upregulation, which could be a possible mechanism underlying the inhibitory effect of ZQD in prostate cancer in patient.

Citing Articles

MicroRNA-143 overexpression enhances the chemosensitivity of A172 glioblastoma cells to carmustine.

Zaer S, Aghamaali M, Najafi S, Hosseini S, Amini M, Doustvandi M Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):533-542.

PMID: 39007927 DOI: 10.1007/s00210-024-03287-1.

Zhoushi Qi Ling decoction inhibits the progression of castration-resistant prostate cancer in vivo by regulating macrophage infiltration via IL6-STAT3 signaling.

Cao H, Wang D, Gao R, Chen L, Feng Y, Sun P J Tradit Complement Med. 2024; 14(1):19-25.

PMID: 38223804 PMC: 10785149. DOI: 10.1016/j.jtcme.2023.05.005.

Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice.

Kong F, Wang C, Zhang J, Wang X, Sun B, Xiao X Chin Herb Med. 2023; 15(4):485-495.

PMID: 38094009 PMC: 10715895. DOI: 10.1016/j.chmed.2023.05.003.

Targeting of AKT1 by miR-143-3p Suppresses Epithelial-to-Mesenchymal Transition in Prostate Cancer.

Armstrong L, Willoughby C, McKenna D Cells. 2023; 12(18).

PMID: 37759434 PMC: 10526992. DOI: 10.3390/cells12182207.

Zhoushi Qiling decoction inhibits proliferation of human prostate cancer cells through IL6/STAT3 pathway.

Cao H, Feng Y, Sun P, Chen L, Wang D, Gao R J Cancer. 2023; 14(12):2246-2254.

PMID: 37576403 PMC: 10414038. DOI: 10.7150/jca.84943.

References

Qian Y, Teng Y, Li Y, Lin X, Guan M, Li Y . MiR-143-3p suppresses the progression of nasal squamous cell carcinoma by targeting Bcl-2 and IGF1R. Biochem Biophys Res Commun. 2019; 518(3):492-499. DOI: 10.1016/j.bbrc.2019.08.075. View

Tsui K, Chang Y, Feng T, Hou C, Lin Y, Yang P . Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells. Prostate. 2017; 78(4):242-249. DOI: 10.1002/pros.23463. View

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

Sakai M, Martinez-Arguelles D, Patterson N, Chaurand P, Papadopoulos V . In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth. PLoS One. 2015; 10(3):e0120670. PMC: 4374753. DOI: 10.1371/journal.pone.0120670. View

Gao W, Yu Y, Cao H, Shen H, Li X, Pan S . Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother. 2010; 64(6):399-408. DOI: 10.1016/j.biopha.2010.01.018. View

Sonpavde G, Spencer D, Slawin K . Vaccine therapy for prostate cancer. Urol Oncol. 2007; 25(6):451-9. DOI: 10.1016/j.urolonc.2007.01.010. View

Damodaran S, Lang J, Jarrard D . Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches. J Urol. 2019; 201(5):876-885. DOI: 10.1097/JU.0000000000000117. View

Wu D, Huang P, Wang L, Zhou Y, Pan H, Qu P . MicroRNA-143 inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in prostate cancer. Mol Med Rep. 2013; 8(2):626-30. DOI: 10.3892/mmr.2013.1501. View

Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z . miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem. 2011; 350(1-2):207-13. DOI: 10.1007/s11010-010-0700-6. View

10.

Chen J, Zhang L, Li C, Chen R, Liu C, Chen M . Lipophilized Epigallocatechin Gallate Derivative Exerts Anti-Proliferation Efficacy through Induction of Cell Cycle Arrest and Apoptosis on DU145 Human Prostate Cancer Cells. Nutrients. 2020; 12(1). PMC: 7020104. DOI: 10.3390/nu12010092. View

11.

Hotte S, Saad F . Current management of castrate-resistant prostate cancer. Curr Oncol. 2010; 17 Suppl 2:S72-9. PMC: 2935714. DOI: 10.3747/co.v17i0.718. View

12.

Clape C, Fritz V, Henriquet C, Apparailly F, Fernandez P, Iborra F . miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One. 2009; 4(10):e7542. PMC: 2763222. DOI: 10.1371/journal.pone.0007542. View

13.

Peschiaroli A, Giacobbe A, Formosa A, Markert E, Bongiorno-Borbone L, Levine A . miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2012; 32(6):797-802. DOI: 10.1038/onc.2012.100. View

14.

Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao Y . MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem. 2012; 287(27):23227-35. PMC: 3391126. DOI: 10.1074/jbc.M112.373084. View

15.

Porkka K, Pfeiffer M, Waltering K, Vessella R, Tammela T, Visakorpi T . MicroRNA expression profiling in prostate cancer. Cancer Res. 2007; 67(13):6130-5. DOI: 10.1158/0008-5472.CAN-07-0533. View

16.

Wu Z, Zhu Q, Yin Y, Kang D, Cao R, Tian Q . Traditional Chinese Medicine CFF-1 induced cell growth inhibition, autophagy, and apoptosis via inhibiting EGFR-related pathways in prostate cancer. Cancer Med. 2018; 7(4):1546-1559. PMC: 5911605. DOI: 10.1002/cam4.1419. View

17.

Lin Y, Fukuchi J, Hiipakka R, Kokontis J, Xiang J . Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res. 2007; 17(6):531-6. DOI: 10.1038/cr.2007.12. View

18.

Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F . microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep. 2010; 24(5):1363-9. DOI: 10.3892/or_00000994. View

19.

McDonnell T, Troncoso P, Brisbay S, Logothetis C, Chung L, Hsieh J . Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992; 52(24):6940-4. View